ORIDIS Biomed GmbH Company Profile

11:42 EDT 20th March 2018 | BioPortfolio

ORIDIS™ Biomed is a biomedical company focusing on the discovery and development of therapeutics and targeted treatment solutions for liver cancer and metabolic diseases of the liver.ORIDIS™ Biomed has built a potent drug discovery and development organization based on its extensive scientific and clinical expertise in the area of liver disease, its proprietary TISSOMICS™ research engine, and a seasoned management team with broad experience in industrial drug discovery and commercial product development. Since its inception, the Company has identified multiple compounds and lead series, resulting in a diversified portfolio of research and development programs.
ORIDIS™ Biomed’s most advanced program for the treatment of primary liver cancer (hepato-cellular cancer, HCC) has identified three compound series. Selection of a clinical candidate is currently ongoing.
Other R&D programs include the optimization and development of compounds for the treatment of oxidative stress involved in metabolic liver diseases, such as non-alcoholic steatohepatitis (NASH) and alcoholic steatohepatitis (ASH).
Since 2001, the Company has proven its ability to consistently feed its research pipeline with compounds and lead series identified by its TISSOMICS™ research engine.
In addition to its strong R&D pipeline, ORIDIS™ Biomed is actively evaluating in-licensing opportunities in the area of liver disease.


Stiftingtalstrasse 3-5


Phone: 43-316-325776
Fax: 43-316-325776 22

News Articles [182 Associated News Articles listed on BioPortfolio]

BioMed X and Roche announce research collaboration in the field of immunology

BioMed X announced the initiation of a new research collaboration with F. Hoffmann-La Roche Ltd in the field of immunology. Within the framework of the agreement, BioMed X will launch a global call fo...

BioMed X and Boehringer Ingelheim start new joint research group

BioMed X announced today the start of a new joint research group with Boehringer Ingelheim at the BioMed X Innovation Center in Heidelberg. The focus of the group will be to identify novel regulatory ...

Q Biomed seeks FDA nod for new cancer bone pain drug facility

A regulatory filing was submitted to the FDA by Q BioMed for the approval of a new manufacturing facility that will produce S -More- 

Q BioMed, Washington Univ. team up in glaucoma

Washington University licensed Q BioMed Inc. an exclusive option to evaluate the growth differentiation factor 15 (GDF15) gene biomarker as a companion diagnostic with the MAN01 small molecule for gla...

THC BioMed Announces LOI to Acquire Farm and Greenhouses in Southern Ontario for Potential Cannabis Production - Video Available on

Vancouver, British Columbia--(Newsfile Corp. - February 16, 2018) - THC BioMed (CSE: THC) (OTCQB: THCBF) (FSE: TFHC), Canada's largest supplier of legal Cannabis Genetics, has entered into a Letter...

Q BioMed nets $5mm via FOPO

Specialty pharmaco Q BioMed Inc. netted $5mm through a follow-on public offering of 1.7mm common shares at $3.20. The company also issued 1.7mm five-year warrants to buy one share at an exercise price...

BeiGene to Generate New mAbs Using Harbour BioMed's Mouse Platform

Beijing's BeiGene licensed multi-year rights to use Harbour BioMed's H2L2 transgenic mouse platform, which generates fully human therapeutic monoclonal antibodies. Harbour BioMed, a Shanghai company, ...

THC BioMed's Subsidiary THC2GO Dispensers Submits Application to Operate Cannabis Retail Stores in Manitoba - Video Available on

Vancouver, British Columbia--(Newsfile Corp. - December 21, 2017) - THC BioMed's (CSE: THC) (OTCQB: THCBF) (FSE: TFHD) subsidiary, THC2GO Dispensers, has officially submitted its application to ope...

PubMed Articles [56 Associated PubMed Articles listed on BioPortfolio]

Correction to: Lonoctocog Alfa: A Review in Haemophilia A.

The article Lonoctocog Alfa: A Review in Haemophilia A, written by Zaina T. Al-Salama and Lesley J. Scott, was originally published Online First without open access. After publication in volume 77...

Corrigendum to "double sword role of EZH2 in leukemia" Biomed. Pharmacother. 98 (2018) 626-635.

Ocular Impression-Taking-Which Material Is Best?

To assess the efficacy and effect on clinical signs of a polyvinylsiloxane (Tresident; Shütz Dental Group GmbH, Germany) compared with an irreversible hydrocolloid (Orthoprint; Zhermack SpA, Badia Po...

Erratum to "Automatic Segmentation of Ultrasound Tomography Image".

[This corrects the article DOI: 10.1155/2017/2059036.].

The Role of Publishers in Prevention of Misconducts in Medical Research: Springer and BioMed Central, Victim or Culprit.

Clinical Trials [47 Associated Clinical Trials listed on BioPortfolio]

Amendment of rTSST-1 Variant Vaccine Phase 1 First-in-man Trail

Toxic Shock Syndrome (TSS) a severe condition with high morbidity and mortality results from the hosts overwhelming inflammatory response and cytokine storm. Staphylococcal superantigen to...

Bioequivalence Study Comparing Two Test Products With One Reference Product, All Containing 5 mg Yohimbine

- Type: Bioequivalence study in male healthy volunteers, therapeutical indication (erectile disfunction) not studied - Products, dosage, and route of administration: ...

XC8 in the Treatment of Patients With Bronchial Asthma

A multicenter, double-blind, randomized, parallel-group comparative Phase II clinical study to assess the efficacy and safety of different doses of XC8 vs Placebo in patients with partly c...

Bioequivalence Study of Linagliptin From Prevaglip 5 mg Tablets(Eva Pharma, Egypt) and Trajenta 5 mg Tablets (Boehringer Ingelheim International GmbH, Germany)

An open label randomized, single dose, two-way crossover bioequivalence study to determine the bioequivalence of Linagliptin from Prevaglip 5 mg tablets(Eva pharma for Pharmaceuticals & Me...

Reproducibility of Malaria Challenge in Healthy Volunteers

This is a prospective, single arm, single intervention safety and immunogenicity study in 6 healthy, malaria-naive adults, conducted to demonstrate the successful implementation of the wel...

Companies [569 Associated Companies listed on BioPortfolio]

ORIDIS Biomed GmbH

ORIDIS™ Biomed is a biomedical company focusing on the discovery and development of therapeutics and targeted treatment solutions for liver cancer and metabolic diseases of the liver.ORIDIS™ Biome...

Biomed Pharmaceuticals

The Company is a leading pharmacy provider of intravenous and injectable medications for patients with chronic disorders. Biomed treats a variety of immune deficient and autoimmun...

BioMed Central Ltd

BioMed Central is an independent publishing house committed to providing immediate open access to peer-reviewed biomedical researchAll original research articles published by BioMed Central are made f...


Biomed AG wurde 1951 in Zürich gegründet und hat sich seither als Handelsunternehmen für pharmazeutische Produkte im Schweizer Markt etabliert. Biomed ist spezialisiert auf den Handel mit rezeptpfl...

Alpine Biomed Corporation

Alpine Biomed is a global leader in specialty diagnostic devices for the gastroenterology and neurology clinical markets. The company produces diagnostic tools used for gastroesophageal reflux diseas...

More Information about "ORIDIS Biomed GmbH" on BioPortfolio

We have published hundreds of ORIDIS Biomed GmbH news stories on BioPortfolio along with dozens of ORIDIS Biomed GmbH Clinical Trials and PubMed Articles about ORIDIS Biomed GmbH for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of ORIDIS Biomed GmbH Companies in our database. You can also find out about relevant ORIDIS Biomed GmbH Drugs and Medications on this site too.

Quick Search


Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Hepatology is the study of liver, gallbladder, biliary tree, and pancreas, and diseases associated with them. This includes viral hepatitis, alcohol damage, cirrhosis and cancer. As modern lifestyles change, with alcoholism and cancer becoming more promi...

Head and neck cancers
Cancer can occur in any of the tissues or organs in the head and neck. There are over 30 different places that cancer can develop in the head and neck area. Mouth cancers (oral cancers)  - Mouth cancer can develop on the lip, the tongue, the floor...

Corporate Database Quicklinks

Searches Linking to this Company Record